Cancer, identified as the leading cause of mortality worldwide, makes use of several conventional

treatments. Considering the complex behaviour of tumours and the involvement of numerous genetic

and cellular factors involved in tumorigenesis and metastasis, there is a need to develop a promising

immunotherapy that targets tumours at both the cellular and genetic levels. Chimeric antigen receptor

(CAR) T cell therapy has emerged as a novel therapeutic T cell engineering practice, in which T-

lymphocytes or T-cells are turned into more efficient cancer-fighting machines . This novel therapy has

rapidly shifted and revolutionized the landscape of treatment for lymphoid malignancies. T cells

derived from patient blood are engineered in vitro to express artificial receptors targeted to a specific

tumour antigen. (CAR) T-cell therapy treats certain cancers by directly identifying the tumour antigen

without the involvement of the major histocompatibility complex.

To Visit Site>> Click Here